Search Results

You are looking at 1 - 1 of 1 items for :

  • "Patient outreach" x
Clear All
Lars Bastholt Department of Oncology R, Odense University Hospital, Odense, Denmark

Search for other papers by Lars Bastholt in
Google Scholar
PubMed
Close
,
Michael C. Kreissl Department of Nuclear Medicine, Augsburg Hospital, Augsburg
Department of Nuclear Medicine, University Hospital Würzburg, Würzburg

Search for other papers by Michael C. Kreissl in
Google Scholar
PubMed
Close
,
Dagmar Führer Department of Endocrinology and Metabolism, University Hospital Essen, Essen, Germany

Search for other papers by Dagmar Führer in
Google Scholar
PubMed
Close
,
Ana L. Maia Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, Porto Alegre

Search for other papers by Ana L. Maia in
Google Scholar
PubMed
Close
,
Laura D. Locati Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan

Search for other papers by Laura D. Locati in
Google Scholar
PubMed
Close
,
Léa Maciel Hospital das Clínicas de Ribeirăo Preto, Ribeirăo Preto, Brazil

Search for other papers by Léa Maciel in
Google Scholar
PubMed
Close
,
Yi Wu Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

Search for other papers by Yi Wu in
Google Scholar
PubMed
Close
,
Kevin N. Heller AstraZeneca, Gaithersburg, Md., USA

Search for other papers by Kevin N. Heller in
Google Scholar
PubMed
Close
,
Alan Webster AstraZeneca, Macclesfield, UK

Search for other papers by Alan Webster in
Google Scholar
PubMed
Close
, and
Rossella Elisei Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Close

.gov No. NCT01298323). Patients were randomized 1:1 to either the experimental arm (inclusion in the patient outreach programme, referred to as ‘outreach') or the control arm (standard AE monitoring schedule, referred to as ‘vandetanib control') using an

Free access